AAV vector platform
Broad intellectual property around two original AAV vectors (AAV.GTX and AAV.GT5) with in vivo proof of concept data
Potential out-licensing opportunities to leverage the technology
Diverse portfolio of internal programs for CNS diseases and monogenic disorders
Cost advantage ; don’t have to pay large license fees, and have sufficient effect with less doses
